AI ECG could spot hidden heart rhythm risk before it strikes

NCT ID NCT07316231

Recruiting now Diagnosis Sponsor: Toho University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether an AI-enhanced 12-lead ECG can better identify people at risk for atrial fibrillation (AF), a major cause of stroke and heart failure. Researchers will enroll 350 adults with AF or atrial tachycardia who are in normal rhythm at the time of ECG recording. The AI analyzes the ECG to estimate hidden AF risk, and the team will track patients for 1-2 years to see if the AI's predictions match actual heart events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AI-enhanced 12-lead ECG
What this could lead to: If successful, this AI tool could help doctors detect hidden atrial fibrillation earlier, potentially preventing strokes and heart failure.
What could go wrong: This is an observational registry, not a treatment trial. The AI's accuracy in real-world settings is still unproven, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AI-ENHANCED 12-LEAD ECG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation atrial tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AI-ENHANCED 12-LEAD ECG

Contacts and locations

Locations

Toho University
RECRUITING

Ōta-ku, Tokyo, 143-8540, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.